Bioventus (BVS) Stock Forecast & Price Target

Bioventus is supported by a resilient core franchise in HA injections, bone graft substitutes, and fracture care, with Durolane growing rapidly since its U.S. launch in 2018 and Exogen remaining a credible bone stimulation asset despite the CMS reimbursement cut. Management’s confidence is reinforced by FY25 results showing over $72 million in free cash flow, up from less than $38 million in 2024, while adj EBITDA margins expanded from low teens in 2022 to over 20% in 2025 and organic revenue grew 7.5%. The outlook is further strengthened by disciplined incremental investment in PNS, PRP, ultrasonics, and international expansion, alongside debt reduction toward below 2x leverage, which should improve capital allocation optionality and support longer-term growth.

Bioventus is viewed negatively because it operates in intensely competitive spinal-fusion and bone-growth markets against larger, better-capitalized rivals such as Johnson & Johnson and Medtronic, which limits share gains and pricing power. Its growth is also vulnerable to costly and time-consuming FDA and global regulatory approvals, reimbursement pressure in the U.S. and abroad, and acquisition-related integration or financing risk. Management’s disclosure that the FY/26 Exogen contract exposure could create a $2-3 million top-line headwind underscores how a single reimbursement change can materially pressure revenue and operating results.